This message is sent to you by FDA Newswatch

USDA New Proposed Rule on BioEngineered (GMO) Food Disclosure

Tuesday, June 30, 2020 10:00 AM PDT | 01:00 PM EDT

Training Duration = 60 min              Sponsored by ComplianceOnline

Click Here to register $229.00

Click Here to register and receive CD recording $399.00

Attend this webinar to learn how to be fully compliant with the USDA Final Rule on Bioengineered Food Disclosure, disclosure requirements in product labeling; disclosure options available to food manufacturers and distributors; symbols to be used and graphic requirements; and the timelines for compliance.

Why Should You Attend:

You will learn how to be fully compliant with the USDA Final Rule on Bioengineered Food Disclosure. It is essential that food professionals understand which foods the USDA has listed as bioengineered and what firms are exempt from the Bioengineered Disclosure Rule.

After attending this webinar, you will know what food products are impacted by the new rule, and what food products are exempt. You will also be able to correctly label bioengineered/GMO (Genetically Modified) foods and non-GMO foods. Understanding the timelines for compliance is essential to ensuring your organization complies with the final rule in time to avoid regulatory enforcement actions.

Areas Covered in the Webinar:

  • Review list of bioengineered foods
  • Understand who is exempt from the bioengineered disclosure rule
  • Incidental additivities
  • Disclosure requirements in product labeling
  • Disclosure options available to food manufacturers and distributors
  • Symbols that are to be used and graphic requirements
  • Electronic or digital link disclosure
  • Small food manufacturers
  • Timelines for bioengineered food disclosure standard compliance

Instructor Profile:

Kelly Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.

Utilizing strategic thinking, risk-based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.